New biological therapies in lymphoma treatment

A tétel rövid nézete
dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorSegman, Irit
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentMegyeri, Attila
dc.contributor.opponentdeptKenézy Kórház, Központi Aneszteziológiai és Intezív Terápiás Osztályhu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.date.accessioned2022-08-15T10:59:48Z
dc.date.available2022-08-15T10:59:48Z
dc.date.created2022-05-06
dc.description.abstractDLBCL is the most common type of aggressive lymphoma NHL. DLBCL is a heterogeneous disease that can arise from de novo or malignant transformation of more indolent lymphomas. The cells in DLBCL are derived from mature naïve B-cells in the germinal center or post germinal center of lymph nodes which are organized in a diffuse pattern and efface the normal nodal architecture. DLBCL can be classified into different entities based on molecular features which have an impact on the prognosis. Gene expression profiling (GEP) categorized DLBCL based on the cell of origin into germinal B-cell like (GBC), activated B-cell like (ABC), or unclassified. The current standard of care for first line treatment of DLBCL is R‐CHOP, can cure approximately 60% to 70% of patients with DLBCL . Despite progress in the upfront treatment relapse rate is reported to be between 30% and 40%. At disease progression or relapse, standard treatment for transplant eligible patients is salvage chemotherapy followed by ASCT. Patients with R/R DLBCL that are transplant ineligible or who have failed SCT have limited therapeutic options and poor prognosishu_HU
dc.description.correctorhbk
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent37hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/336473
dc.language.isoenhu_HU
dc.subjectpolatuzumab vedotinhu_HU
dc.subjectCART
dc.subjectSCHOLAR-1
dc.subject.dspaceDEENK Témalistahu_HU
dc.titleNew biological therapies in lymphoma treatmenthu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)